Biogen Idec Reveals Clinical Data for (Really) Small Oral MS Drug BG-12
Nov02

Biogen Idec Reveals Clinical Data for (Really) Small Oral MS Drug BG-12

Biogen Idec made a splash last week when its oral medication for multiple sclerosis (MS), BG-12, was found to reduce relapses in 44-53% of nearly 3,800 patients in two separate Phase 3 clinical trials (CONFIRM and DEFINE, respectively). Continued hopes for an orally available, non-injectable MS treatment have created a race between Biogen Idec and several other firms, as C&EN’s Lisa Jarvis examines in a 2009 MS cover story. In...

Read More

Biogen Taps Exelixis’ Scangos–Updated

Reuters and several other news outlets are reporting that Exelixis CEO George Scangos is being tapped as the next leader of Biogen Idec. It’s a curious choice, to say the least. Scangos heads up a small molecule, oncology-focused biotech that has yet to commercialize a product, and Biogen Idec has several biologic drugs on the market and multi-billion dollar sales. So why Scangos? My only thought is that Biogen has been wanting for...

Read More

Is Incubation a Win for Big Pharma?

Johnson & Johnson appears to be the next big pharma company looking to test out the incubator model as one way to spur innovation. According to an article in the San Diego Business Journal, the big pharma company is interested in renting space to entrepreneurs that would have access to J&J’s equipment and technology at its research site in La Jolla, Calif. Diego Miralles, facility head at La Jolla, tells the SDBJ that up to 17...

Read More